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Lysyl-oxidase in systemic sclerosis-associated
pulmonary arterial hypertension: a future still to be
written
This editorial refers to Lysyl oxidase, a possible role in
systemic sclerosis associated pulmonary hyperten-
sion. A multicentre study, Vadasz et al., doi:10.1093/
rheumatology/kez035
The study performed by Vadasz et al. [1] published in this
issue of Rheumatology gives some interesting insights
into the typical vasculopathy in the context of systemic
sclerosis (SSc). Vasculopathy is a hallmark of SSc [2].
Vascular abnormalities, including endothelial injury, vas-
cular remodelling with neointimal hyperplasia, pericytes
and vascular smooth muscle cells proliferation, capillary
loss and ineffective angiogenesis are present from the
early stages of the disease [2]. Despite vasculopathy
being a generalized process in SSc, vascular complica-
tions other than Raynaud’s phenomenon occur only in a
subset of subjects [2]. The different vascular complica-
tions do not always coexist in the same patients, but the
factors that influence the appearance of vascular compli-
cations in specific territories remain to be identified [2].
Lysyl oxidases (LOXs) are a family of five copper-de-
pendent amine oxidases composed by LOX and four
LOX-like enzymes (LOXL1-4). Enzymatic activity results
in covalent crosslinking of extracellular proteins, yielding
to increased tensile strength and resistance to proteolysis.
LOXs play a role in several crucial physiological functions,
including cell adhesion and motility, morphogenesis,
maintenance of structural integrity, tissue repair,
neoangiogenesis and vascular remodelling, epithelial-to-
mesenchymal transition and endothelial-to-mesenchymal
transition (endoMT) [3]. Moroever, LOXs favour the stabil-
ization of atherosclerotic plaques [4], and limits aneurysm
dilatation [5]. LOXs dysregulation is proposed to have a
role in multiple pathological fibrotic conditions, such as
liver cirrhosis, pulmonary fibrosis and heart failure, and
in idiopathic pulmonary hypertension (iPAH); a condition
characterised by a proliferative and obliterative remodel-
ling of the lung vasculature.
Given the role of LOXs in fibrosis and vascular disordes,
it is logical to hypothesize a dysregulation of LOXs in SSc.
The multicentre study performed by Vadasz et al. [1] pub-
lished in this issue of Rheumatology is the first in-depth
analysis aiming to identify clinical correlates of high serum
LOX in SSc. The authors studied the levels of LOX in the
sera of 86 Israeli patients with established SSc, 86 Italian
patients with very early SSc, 110 patients with primary
Raynaud’s phenomenon and 80 healthy subjects. The au-
thors found higher serum levels of LOX in established SSc
than in the other groups, although serum levels of LOX
were similar in limited cutaneous (lcSSc) and diffuse cuta-
neous SSc (dcSSc). Interestingly, higher serum levels of
LOX were associated with pulmonary hypertension as
estimated by echocardiography or assessed by right
heart catheterization. The authors failed to verify any rela-
tion between serum levels of LOX and other vascular or
fibrotic features (such as digital ulcers, capillaroscopic
pattern, heart involvement, mRSS or interstitial lung dis-
ease) as well as with disease duration or concurrent medi-
cations, with the exception of a positive correlation with
disease severity as assessed by Medsger disease severity
scale and a prediction of poor prognosis during follow-up.
To identify the potential origin of serum LOX in SSc, the
authors studied LOX expression in tissue specimens of
subjects not enrolled in the first part of the study: they
observed a similar LOX expression in the skin of patients
with long-standing dcSSc as compared with controls. On
the contrary, they found high LOX expression in lungs with
SSc-associated PAH (SSc-APAH) and in a case of SSc-
associated interstitial lung disease. Confocal immunofluor-
escence of lung specimens revealed predominant LOX
expression in the remodelled vasculature. The authors
propose that lung involvement, and SSc-APAH in particu-
lar, is an important source of LOX expression in SSc.
Unfortunately, prospective serum sampling was not avail-
able, thus limiting the power of the analysis in the identi-
fication of other clinical correlates of high serum LOX.
In summary, the study raises the possibility that
LOXs might be involved not only in immune-related
fibrosis but also in vasculopathy, and might represent a
link between vasculopathy and tissue fibrosis in SSc
(see Fig. 1). The mechanisms remain to be understood,
although it should be rational to hypothesise a role
for EndoMT, a process induced by LOXs by which endo-
thelial cells transdifferentiate to acquire mesenchymal
properties, which applies to both fibrosis and vasculopa-
thy in SSc [6].
Further studies are required to verify if LOXs could rep-
resent valuable disease biomarkers and important thera-
peutic targets to limit fibrosis and vascular remodelling
without affecting SSc immune dysregulation. Future re-
search should address several questions, including:
(i) the relative contribution of the LOX and the different
LOXL molecules and propeptides to fibrosis and
vasculopathy; (ii) the relationship between plasma levels
and tissue expression of the different LOXs; (iii) the dis-
section of whether LOX activity is particularly relevant in
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specific disease phases—such as during the early phase
of fibrosis establishment—that might represent a window
of opportunity for targeted therapies; and (iv) the possibil-
ity of differentially modulating the pathogenic Vs protect-
ive activities of LOXs by targeting specific LOX isoforms in
a specific temporal and/or spatial window.
SSc-APAH dramatically impacts the prognosis of pa-
tients affected by SSc [7]. Recent data have shown that
patients with very early pulmonary vascular remodelling
as assessed by a mean pulmonary pressure (mPAP) be-
tween 2124mmHg at rest or by exercise pulmonary
hypertension (mPAP at peak exercise 5 30mmHg and
total pulmonary resistance >3 Wood Units), experience
lower exercise capacity [8] and poorer outcomes [9]. In
an effort to limit diagnostic delays, the 6th World
Symposium for Pulmonary Hypertension proposed to
lower the cut-off to define pulmonary hypertension
from 25 to 20mmHg of mean pulmonary pressure
(mPAP) [10]. An unmet need in SSc is the identification
of non-invasive biomarkers of PAH. The work performed
by Vadasz et al. suggests that molecules involved in
vascular remodelling may be used to identify biomarkers
of early pulmonary vasculopathy in SSc. Future studies
are required to assess whether LOXs might be relevant
for this purpose.
In conclusion, the study conducted by Vadasz et al. [1]
on LOXs addresses a rational and potentially exciting re-
search topic in SSc. Despite promising findings, most of
the work remains to be done and the future of this topic
remains to be written.
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FIG. 1 Lysyl oxidases as a possible link between fibrosis and vasculopathy
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